Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sema4 Holdings Corp. - Warrant
(NQ:
SMFRW
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 9, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
0.0181 (200)
Ask (Size)
0.0260 (40)
Prev. Close
0.0240
Today's Range
N/A - N/A
52wk Range
N/A - N/A
Shares Outstanding
105,429
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance
January 09, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference
December 30, 2022
Sema4|GeneDx President & Chief Executive Officer, Katherine Stueland, to deliver presentation
From
Sema4
Via
GlobeNewswire
Performance
More News
Read More
New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU
December 05, 2022
From
Sema4
Via
GlobeNewswire
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
November 14, 2022
From
Sema4
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bed Bath & Beyond, Sema4, Medtronic, and Palantir and Encourages Investors to Contact the Firm
November 06, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022
November 04, 2022
From
Sema4
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kohl’s, Bed Bath & Beyond, Sema4, and Medtronic and Encourages Investors to Contact the Firm
October 31, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies
October 31, 2022
From
Sema4
Via
GlobeNewswire
Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns
October 27, 2022
From
Sema4
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kohl’s, Bed Bath & Beyond, Sema4, and Medtronic and Encourages Investors to Contact the Firm
October 26, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels
October 26, 2022
From
Sema4
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against TuSimple, Kohl’s, Bed Bath & Beyond, and Sema4 and Encourages Investors to Contact the Firm
October 21, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm
October 16, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders
October 13, 2022
From
Sema4
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm
October 11, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm
October 06, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study
October 05, 2022
From
Sema4
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm
October 02, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTOR NOTICE: Sema4 Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SMFR; SMFRW
September 20, 2022
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Investor Alert: Sema4 Holdings Corp. (SMFR, SMFRW) Class Action - Bronstein, Gewirtz & Grossman, LLC, A Prominent Firm, Encourages Shareholders to Actively Participate
September 16, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Sema4 Holdings Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SMFR, SMFRW
September 13, 2022
From
The Rosen Law Firm, P.A.
Via
Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Sema4 Holdings Corp. (SMFR, SMFRW) Investors
September 12, 2022
From
The Law Offices of Frank R. Cruz
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm
September 09, 2022
Via
ACCESSWIRE
SEMA4 ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sema4 Holdings Corp. and Encourages Investors to Contact the Firm
September 08, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
SEMA4 ALERT: Bragar Eagel & Squire, P.C. is Investigating Sema4 Holdings Corp. on Behalf of Sema4 Stockholders and Encourages Investors to Contact the Firm
August 18, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Frequently Asked Questions
Is Sema4 Holdings Corp. - Warrant publicly traded?
Yes, Sema4 Holdings Corp. - Warrant is publicly traded.
What exchange does Sema4 Holdings Corp. - Warrant trade on?
Sema4 Holdings Corp. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for Sema4 Holdings Corp. - Warrant?
The ticker symbol for Sema4 Holdings Corp. - Warrant is SMFRW on the Nasdaq Stock Market
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.